hydroxychloroquine and tamoxifen

hydroxychloroquine has been researched along with tamoxifen in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL1
Garralda Luquin, A1
Bally, MB; Donohue, E; Dragowska, WH; Gelmon, KA; Gorski, SM; Kapanen, AI; Qadir, MA; Rawji, JS; Roberge, M; Wang, JC; Warburton, C; Weppler, SA; Wong, LY1
Clarke, PA; Clarke, R; Cook, KL; Cruz, MI; Soto-Pantoja, DR; Wärri, A; Zwart, A1
Abdulaziz, N; McCune, WJ; Shah, AR1
Defoort-Dhellemmes, S1
Chiang, TK; Kurup, SK; White, KM; Yu, M1

Reviews

5 review(s) available for hydroxychloroquine and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
    Medicinal research reviews, 2021, Volume: 41, Issue:1

    Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization

2021
[Ocular toxicity induced by medication].
    Anales del sistema sanitario de Navarra, 2008, Volume: 31 Suppl 3

    Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Estrogen Antagonists; Humans; Hydroxychloroquine; Tamoxifen

2008
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
    Current opinion in rheumatology, 2018, Volume: 30, Issue:3

    Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hydroxychloroquine; Mass Screening; Renal Insufficiency; Retinal Diseases; Retrospective Studies; Rheumatic Diseases; Risk Factors; Tamoxifen; Tomography, Optical Coherence

2018
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.
    Biomolecules, 2022, 09-29, Volume: 12, Issue:10

    Topics: Amiodarone; Cefuroxime; Chlorpromazine; Cisplatin; Deferoxamine; Digoxin; Electrophysiology; Ethambutol; Evoked Potentials, Visual; Humans; Hydroxychloroquine; Isotretinoin; Optic Nerve; Phosphodiesterase 5 Inhibitors; Quinine; Retina; Tamoxifen; Thioridazine; Topiramate; Vigabatrin

2022

Other Studies

3 other study(ies) available for hydroxychloroquine and tamoxifen

ArticleYear
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Cadaverine; Cell Line, Tumor; Cell Survival; Cytoplasmic Vesicles; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Gene Silencing; Humans; Hydroxychloroquine; Membrane Proteins; Mice; Phagosomes; Quinazolines; RNA, Small Interfering; Signal Transduction; Staining and Labeling; Tamoxifen; Treatment Outcome; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays

2013
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Macrophages; Mice; Mice, Nude; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
    Journal francais d'ophtalmologie, 2020, Volume: 43, Issue:6

    Topics: Antimalarials; Betacoronavirus; Bone Density Conservation Agents; Contraindications, Drug; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; Obesity; Pandemics; Pneumonia, Viral; Renal Insufficiency; Retinal Diseases; Risk Factors; SARS-CoV-2; Tamoxifen

2020